Table 4 Treatment and outcomes of patients with MDR/RR/pre-XDR-TBTB using bedaquiline or delamanid or none.

From: Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid

Characteristics

Total (n = 101)

Bedaquiline (n = 32)

Delamanid (n = 25)

Non-bedaquiline or delamanid (n = 44)

χ2/Z/H

P value

Treatment

      

 Number of drugs administered, including bedaquiline and/or Delamanid [median (Q1, Q3)]

6.00 (5.00, 6.00)

6.00 (5.25, 6.00)

6.00 (6.00, 6.00)

5.00 (5.00, 6.00)

18.210a

< 0.001

 Treatment with any FQ, N (%)

78 (77.2)

15 (46.9)

21 (84.0)

42 (95.5)

25.727

< 0.001

 Treatment with linezolid, N (%)

73 (72.3)

28 (87.5)

25 (100)

20 (45.5)

29.088

< 0.001

 Early stopping of new drug due to adverse events before 24-week use, N (%) (n = 57)

1 (3.1)

0 (0)

 Interventional therapy

10 (9.9)

4 (12.5)

3 (12.0)

3 (6.8)

1.033b

0.695

 Surgical resection

5 (5.0)

1 (3.1)

0 (0)

4 (9.1)

2.390b

0.310

 Duration of use of bedaquiline or delamanid in weeks, median (Q1, Q3)

24.00 (24.00, 24.00)

24.00 (24.00, 26.00)

− 1.934a

0.053

 Duration of MDR/RR/Pre-XDR-TBTB treatment in weeks, median (Q1, Q3) (n = 92)

80.00 (72.00, 96.00)

86.00 (73.00, 104.00)

74.00 (72.50, 78.00)

81.50 (72.00, 97.50)

6.484a

0.039

Treatment outcomes, N (%)

      

 Cured

67 (66.3)

23 (71.9)

19 (76.0)

25 (56.8)

3.270

0.195

 Completed

25 (24.8)

8 (25.0)

2 (8.0)

15 (34.1)

5.828

0.054

 Failure

0 (0)

0 (0)

0 (0)

0 (0)

 Died

0 (0)

0 (0)

0 (0)

0 (0)

-

 Not evaluated

3 (3.0)

0 (0)

0 (0)

3 (6.8)

2.629b

0.334

 Loss to follow-up

6 (5.9)

1 (3.1)

4 (16.0)

1 (2.3)

4.769b

0.067

 Treatment success

92 (91.1)

31 (96.9)

21 (84.0)

40 (90.9)

2.768b

0.210

Culture outcomes, N (%) (n = 85)

n = 85

n = 31

n = 18

n = 36

  

 Culture conversion, N (%) (n = 85)

83(97.6)

31 (100)

18 (100)

34 (94.4)

1.875b

0.506

 Cultrue conversion after 2 months of treatment, N (%) (n = 85)

57 (67.1)

28 (90.3)

14 (77.8)

15 (41.7)

17.247

< 0.001

 Cultrue conversion at 6 months of treatment, N (%) (n = 85)

74 (87.1)

30 (96.8)

18 (100)

26 (72.2)

9.001b

< 0.001

 Median time to culture conversion, weeks (95% CI)c

4.00 (2.00, 12.00)

2.00 (2.00, 8.00)

2.00 (2.00, 8.00)

12.00 (7.00, 24.00)

26.492a

 < 0.001

Outcomes of chest CT imaging features

      

Outcomes of atelectasis at the end of treatment in CT images, N (%) (n = 36)d

n = 36

n = 5

n = 11

n = 20

4.184a

0.123

 Constant

6 (16.7)

2 (40.0)

3 (27.3)

1 (5.0)

  

 Partially reexpansion

11 (30.6)

2 (40.0)

2 (18.2)

7 (35.0)

  

 Completely reexpansion

14 (38.9)

1 (20.0)

5 (45.5)

8 (40.0)

  

 Deterioration

2 (5.6)

0 (0)

1 (9.1)

1 (5.0)

  

 Receiving surgery

3 (8.3)

0 (0)

0 (0)

3 (15.0)

  

Outcomes of stenosis at the end of treatment in CT images, N (%) (n = 60)e

n = 60

n = 19

n = 14

n = 27

13.903a

0.001

 Constant

24 (40.0)

14 (73.7)

4 (28.6)

6 (22.2)

  

 Improved

30 (50)

5 (26.3)

9 (64.3)

16 (59.3)

  

 Deterioration

4 (6.7)

0 (0)

1 (7.1)

3 (11.1)

  

 Surgery

2 (3.3)

0 (0)

0 (0)

2 (7.4)

  

Outcomes of pulmonary cavities at the end of treatment, N (%) (n = 54)f

n = 54

n = 18

n = 11

n = 25

0.982a

0.612

 Constant

3 (5.6)

1 (5.6)

0 (0)

2 (8.0)

  

 Cavity reduction

14 (25.9)

6 (33.3)

3 (27.3)

5 (20.0)

  

 Cavity closure

32 (59.3)

10 (55.6)

8 (72.7)

14 (56.0)

  

 Cavity cleaning

2 (3.7)

0 (0)

0 (0)

2 (8.0)

  

 Deterioration

1 (1.9)

1 (5.6)

0 (0)

0 (0)

  

 Surgery

2 (3.7)

0 (0)

0 (0)

2 (8.0)

  
  1. FQ fluoroquinolone, IQR interquartile range, MDR-TBTB multidrug-resistant tracheobronchial tuberculosis, MDR/RR/pre-XDR-TBTB multidrug-resistant/rifampicin-resistant/pre-extensively-drug resistant tracheobronchial tuberculosis, RR-TBTB rifampicin-resistant tracheobronchial tuberculosis.
  2. aKruskal-Wallis H Test.
  3. bFisher Exact Test.
  4. c80 patients were included and 5 patients were excluded (2 patients had unknown culture conversion results; 3 patients had a sputum culture monitoring frequency exceeded two months after 6 months of treatment).
  5. d36 patients with baseline atelectasis underwent chest image at the end of treatment.
  6. e60 patients with baseline stenosis underwent chest image at the end of treatment.
  7. f54 patients with baseline pulmonary cavities underwent chest image at the end of treatment.